Glucose Control May Influence Outcome Of Ranibizumab Treatment For Diabetic Macular Edema.

Image via Wikipedia

According to a study published in the Journal of Diabetes and its Complications, glucose control influences the outcome of ranibizumab treatment for diabetic macular edema.

This retrospective study enrolled 65 eyes of 65 patients with persistent DME treated with intravitreal ranibizumab injection. The main outcome measures were the change in best corrected visual acuity (BCVA), the central subfield macular thickness (CSMT) recorded with optical coherence tomography (OCT), and its correlation with the serum hemoglobin A1c values (HbA1c).

Researchers found that serum levels of glycated hemoglobin (HbA1c) showed a negative correlation with the change in central subfield macular thickness (CSMT) after intravitreal injection of ranibizumab.

Posted in: Diabetic retinopathy, Macular Degeneration, Visual acuity